Positive results have been presented from the primary analysis of the ongoing RAINBOWFISH study assessing the efficacy and safety of Evrysdi (risdiplam) in babi 4 October 2023
Information from research group GlobalData suggests there is a pressing need for innovation and collaboration in China to address an unmet medical need in Fabry 29 September 2023
New Jersey, USA-based Merck & Co has been granted a Priority Review from the US regulator for its pulmonary arterial hypertension (PAH) candidate sotatercept. 29 September 2023
A $250 million private financing for California’s BridgeBio Pharma will support a possible launch of acoramidis, as well as further late-stage pipeline developm 26 September 2023
Swiss pharma major Novartis has announced the Phase III NETTER-2 trial of Lutathera (lutetium Lu 177 dotatate) has met its primary endpoint. 25 September 2023
Swiss pharma firm Acino has acquired M8 Pharmaceuticals, a specialty biopharmaceutical company focused on licensing, marketing, and distributing innovative and 20 September 2023
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.